The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Posaconazole as Salvage Therapy for Zygomycosis
Open accessAbstract
Zygomycosis, an infection that is associated with significant morbidity and mortality, is becoming common in immunocompromised patients. Posaconazole is a new extended-spectrum azole antifungal that has demonstrated in vitro and in vivo activity against zygomycetes. This report provides the results from the first 24 patients with active zygomycosis who were enrolled in two open-label, nonrandomized, multicentered compassionate trials that evaluated oral posaconazole as salvage therapy for invasive fungal infections. Posaconazole was usually given as an oral suspension of 200 mg four times a day or 400 mg twice a day. Eleven (46%) of the infections were rhinocerebral. Duration of posaconazole therapy ranged from 8 to 1,004 days (mean, 292 days; median, 182 days). Rates of successful treatment (complete cure and partial response) were 79% in 19 subjects with zygomycosis refractory to standard therapy and 80% in 5 subjects with intolerance to standard therapy. Overall, 19 of 24 subjects (79%) survived infection. Survival was also associated with surgical resection of affected tissue and stabilization or improvement of the subjects' underlying illnesses. Failures either had worsening of underlying illnesses or requested all therapy withdrawn; none of the failures received more than 31 days of posaconazole. Posaconazole oral solution was well tolerated and was discontinued in only one subject due to a drug rash. Posaconazole appears promising as an oral therapy for zygomycosis in patients who receive required surgery and control their underlying illness.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiology and Outcome of Zygomycosis: A Review of 929 Reported Cases
Roden, M. M., Zaoutis, T. E., Buchanan, W. L., Knudsen, T. A., Sarkisova, T. A., Schaufele, R. L., Sein, M., Sein, T., Chiou, C. C., Chu, J. H., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/432579 · Cited by 3,044
Ascioglu, S., Rex, J. H., de Pauw, B., Bennett, J. E., Bille, J., Crokaert, F., Denning, D. W., Donnelly, J. P., Edwards, J. E., Erjavec, Z., et al. (2002) · Clinical Infectious Diseases · doi:10.1086/323335 · Cited by 2,331
Ribes, J. A., Vanover-Sams, C. L., & Baker, D. J. (2000) · Clinical Microbiology Reviews · doi:10.1128/cmr.13.2.236 · Cited by 1,711
Epidemiology and Outcome of Mould Infections in Hematopoietic Stem Cell Transplant Recipients
Marr, K. A., Carter, R. A., Crippa, F., Wald, A., & Corey, L. (2002) · Clinical Infectious Diseases · doi:10.1086/339202 · Cited by 1,448
Self-citationInfections in Patients with Diabetes Mellitus
Joshi, N., Caputo, G. M., Weitekamp, M. R., & Karchmer, A. W. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912163412507 · Cited by 1,043
Voriconazole Treatment for Less‐Common, Emerging, or Refractory Fungal Infections
Perfect, J. R., Marr, K. A., Walsh, T. J., Greenberg, R. N., DuPont, B., de la Torre‐Cisneros, J., Just‐Nubling, G., Schlamm, H. T., Lutsar, I., Espinel‐Ingroff, A., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/374557 · Cited by 680
Self-citationKontoyiannis, D. P., Lionakis, M. S., Lewis, R. E., Chamilos, G., Healy, M., Perego, C., Safdar, A., Kantarjian, H., Champlin, R., Walsh, T. J., et al. (2005) · The Journal of Infectious Diseases · doi:10.1086/428780 · Cited by 674
Self-citationWalsh, T. J., Hiemenz, J. W., Seibel, N. L., Perfect, J. R., Horwith, G., Lee, L., Silber, J. L., DiNubile, M. J., Reboli, A., Bow, E., et al. (1998) · Clinical Infectious Diseases · doi:10.1086/516353 · Cited by 629
Infections due to emerging and uncommon medically important fungal pathogens
Walsh, T. J., Groll, A., Hiemenz, J., Fleming, R., Roilides, E., & Anaissie, E. (2004) · Clinical Microbiology and Infection · doi:10.1111/j.1470-9465.2004.00839.x · Cited by 601
Zygomycosis in the 1990s in a Tertiary-Care Cancer Center
Kontoyiannis, D. P., Wessel, V. C., Bodey, G. P., & Rolston, K. V. I. (2000) · Clinical Infectious Diseases · doi:10.1086/313803 · Cited by 521
Marty, F. M., Cosimi, L. A., & Baden, L. R. (2004) · New England Journal of Medicine · doi:10.1056/nejm200402263500923 · Cited by 426
Pfaller, M. A., Messer, S. A., Hollis, R. J., & Jones, R. N. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.4.1032-1037.2002 · Cited by 404
Breakthrough Fungal Infections in Stem Cell Transplant Recipients Receiving Voriconazole
Imhof, A., Balajee, S. A., Fredricks, D. N., Englund, J. A., & Marr, K. A. (2004) · Clinical Infectious Diseases · doi:10.1086/423274 · Cited by 402
Self-citationPulmonary Mucormycosis: The Last 30 Years
Lee, F. Y. W., Mossad, S. B., & Adal, K. A. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.12.1301 · Cited by 369
Sun, Q. N., Fothergill, A. W., McCarthy, D. I., Rinaldi, M. G., & Graybill, J. R. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.5.1581-1582.2002 · Cited by 365
Husain, S., Alexander, B. D., Munoz, P., Avery, R. K., Houston, S., Pruett, T., Jacobs, R., Dominguez, E. A., Tollemar, J. G., Baumgarten, K., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/375822 · Cited by 337
In vitro susceptibilities of zygomycetes to conventional and new antifungals
Dannaoui, E. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg020 · Cited by 314
Siwek, G. T., Dodgson, K. J., de Margarida, M.-S., Bartelt, L. A., Kilborn, S. B., Hoth, P. L., Diekema, D. J., & Pfaller, M. A. (2004) · Clinical Infectious Diseases · doi:10.1086/422723 · Cited by 293
Ten Years' Experience in Zygomycosis at a Tertiary Care Centre in India
Chakrabarti, A., Das, A., Sharma, A., Panda, N., Das, S., Gupta, K. L., & Sakhuja, V. (2001) · Journal of Infection · doi:10.1053/jinf.2001.0831 · Cited by 249
Histologic Features of Zygomycosis: Emphasis on Perineural Invasion and Fungal Morphology
Frater, J. L., Hall, G. S., & Procop, G. W. (2001) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2001-125-0375-hfoz · Cited by 227
Maertens, J., Demuynck, H., Verbeken, E., Zachée, P., Verhoef, G., Vandenberghe, P., & Boogaerts, M. (1999) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1701885 · Cited by 213
Jeu, L., Piacenti, F. J., Lyakhovetskiy, A. G., & Fung, H. B. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80126-1 · Cited by 213
A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations
Barrett, J. P., Vardulaki, K. A., Conlon, C., Cooke, J., Daza-Ramirez, P., Evans, E. G. V., Hawkey, P. M., Herbrecht, R., Marks, D. I., Moraleda, J. M., et al. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80125-x · Cited by 190
Self-citationIn Vivo Activity of Posaconazole against Mucor spp. in an Immunosuppressed-Mouse Model
Sun, Q. N., Najvar, L. K., Bocanegra, R., Loebenberg, D., & Graybill, J. R. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.7.2310-2312.2002 · Cited by 184
Gonzalez, C. E., Rinaldi, M. G., & Sugar, A. M. (2002) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(02)00037-5 · Cited by 166
Self-citationActivity of Posaconazole in Treatment of Experimental Disseminated Zygomycosis
Dannaoui, E., Meis, J. F. G. M., Loebenberg, D., & Verweij, P. E. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.11.3647-3650.2003 · Cited by 159
Pharmacokinetics of Posaconazole Coadministered with Antacid in Fasting or Nonfasting Healthy Men
Courtney, R., Radwanski, E., Lim, J. M., & Laughlin, M. A. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.3.804-808.2004 · Cited by 154
Treatment of 21 Cases of Invasive Mucormycosis with Amphotericin B Colloidal Dispersion
Herbrecht, R., Letscher‐Bru, V., Bowden, R. A., Kusne, S., Anaissie, E. J., Graybill, J. R., Noskin, G. A., Oppenheim, B. A., Andrès, E., & Pietrelli, L. A. (2001) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s100960100528 · Cited by 142
Self-citationCryptococcosis in Patients with Cancer
Kontoyiannis, D. P., Ludwig‐Peitsch, W., Reddy, B. T., Whimbey, E. E., Han, X.-Y., Bodey, G. P., & Rolston, K. V. (2001) · Clinical Infectious Diseases · doi:10.1086/320524 · Cited by 117
Garcia‐Diaz, J., Palau, L. A., & Pankey, G. A. (2001) · Clinical Infectious Diseases · doi:10.1086/320767 · Cited by 75
Cluster of Pulmonary Infections Caused byCunninghamella bertholletiaein Immunocompromised Patients
Rickerts, V., Böhme, A., Viertel, A., Behrendt, G., Jacobi, V., Tintelnot, K., & Just‐Nübling, G. (2000) · Clinical Infectious Diseases · doi:10.1086/318144 · Cited by 62
Safdar, A., O'Brien, S. M., & Kouri, I. F. (2004) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704552 · Cited by 39
Combined Antifungal Treatment of Visceral Mucormycosis with Caspofungin and Liposomal Amphotericin B
Voitl, P., Scheibenpflug, C., Weber, T., et al. (2002) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-002-0781-6 · Cited by 32
Fungal infections in marrow transplant recipients under antifungal prophylaxis with fluconazole
de Oliveira, J. S. R., Kerbauy, F. R., Colombo, A. L., Kerbauy, D. M. B., Pinheiro, G. S., Silva, M. R. R., Ribeiro, M. S. S., Raineri, G., & Kerbauy, J. (2002) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2002000700005 · Cited by 32
Eisen, D. P., & Robson, J. (2004) · Mycoses · doi:10.1111/j.1439-0507.2004.00959.x · Cited by 31
Eradication of Invasive Mucormycosis--Effectiveness of the Echinocandin FK463
Jacobs, P., Wood, L., du Toit, A., et al. (2003) · Hematology · doi:10.1080/1024533031000090810 · Cited by 27
Disseminated Zygomycosis Due to Rhizopus schipperae after Heatstroke
Anstead, G. M., Sutton, D. A., Thompson, E. H. Z., et al. (1999) · Journal of Clinical Microbiology · doi:10.1128/jcm.37.8.2656-2662.1999 · Cited by 23
Self-citation
Cited by
Cornely, O. A., Alastruey-Izquierdo, A., Arenz, D., Chen, S. C. A., Dannaoui, E., Hochhegger, B., Hoenigl, M., Jensen, H. E., Lagrou, K., Lewis, R. E., et al. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(19)30312-3 · Cited by 1,820
(2006) · PubMed · Cited by 906
Epidemiology of Invasive Mycoses in North America
Pfaller, M. A., & Diekema, D. J. (2010) · Critical Reviews in Microbiology · doi:10.3109/10408410903241444 · Cited by 901
ESCMID† and ECMM‡ joint clinical guidelines for the diagnosis and management of mucormycosis 2013
Cornely, O. A., Arikan-Akdagli, S., Dannaoui, E., Groll, A. H., Lagrou, K., Chakrabarti, A., Lanternier, F., Pagano, L., Skiada, A., Akova, M., et al. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12371 · Cited by 863
Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis
Marty, F. M., Ostrosky-Zeichner, L., Cornely, O. A., Mullane, K. M., Perfect, J. R., Thompson, G. R., Alangaden, G. J., Brown, J. M., Fredricks, D. N., Heinz, W. J., et al. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)00071-2 · Cited by 704
Self-citation
Metadata
- Authors
- Greenberg, R. N., Mullane, K., van Burik, J.-A. H., Raad, I., Abzug, M. J., Anstead, G., Herbrecht, R., Langston, A., Marr, K. A., Schiller, G., Schuster, M., Wingard, J. R., Gonzalez, C. E., Revankar, S. G., Corcoran, G., Kryscio, R. J., & Hare, R.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2006-01
- Volume
- 50
- Issue
- 1
- Pages
- 126-133
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2108597723
- Cited by
- 555
- References
- 37
- FWCI
- 24.81
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.